MX360727B - Composiciones y metodos para evitar la agregacion del vector aav. - Google Patents

Composiciones y metodos para evitar la agregacion del vector aav.

Info

Publication number
MX360727B
MX360727B MX2014006734A MX2014006734A MX360727B MX 360727 B MX360727 B MX 360727B MX 2014006734 A MX2014006734 A MX 2014006734A MX 2014006734 A MX2014006734 A MX 2014006734A MX 360727 B MX360727 B MX 360727B
Authority
MX
Mexico
Prior art keywords
aggregation
virions
compositions
methods
solutions
Prior art date
Application number
MX2014006734A
Other languages
English (en)
Spanish (es)
Inventor
John Fraser Wright
Guang Qu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360727(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX360727B publication Critical patent/MX360727B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
MX2014006734A 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav. MX360727B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
PCT/US2005/019235 WO2005118792A1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Publications (1)

Publication Number Publication Date
MX360727B true MX360727B (es) 2018-11-14

Family

ID=35462907

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014006734A MX360727B (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MXPA06014030A MXPA06014030A (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MX2019006353A MX2019006353A (es) 2004-06-01 2006-11-30 Composiciones y metodos para evitar la agregacion del vector aav.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MXPA06014030A MXPA06014030A (es) 2004-06-01 2005-06-01 Composiciones y metodos para evitar la agregacion del vector aav.
MX2019006353A MX2019006353A (es) 2004-06-01 2006-11-30 Composiciones y metodos para evitar la agregacion del vector aav.

Country Status (11)

Country Link
US (4) US7704721B2 (https=)
EP (3) EP1751275B1 (https=)
JP (5) JP2008501339A (https=)
BR (1) BRPI0511764B8 (https=)
CA (1) CA2569244C (https=)
CY (1) CY1125798T1 (https=)
DK (2) DK3290513T3 (https=)
ES (2) ES2932278T3 (https=)
HU (2) HUE035418T2 (https=)
MX (3) MX360727B (https=)
WO (1) WO2005118792A1 (https=)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
DK2529020T3 (en) * 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
CA2829774C (en) * 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
JP6348064B2 (ja) 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター
US20140349403A1 (en) 2011-12-12 2014-11-27 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
BR112015031541A2 (pt) 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
CN105765066B (zh) * 2013-11-29 2018-12-14 宝生物工程株式会社 用于定量腺伴随病毒的方法
ES2744565T3 (es) 2014-04-25 2020-02-25 Genethon Tratamiento de la hiperbilirrubinemia
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10526583B2 (en) 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
SG11201703148TA (en) 2014-11-05 2017-05-30 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
SG11201704919SA (en) * 2015-01-13 2017-07-28 Alfa Wassermann Inc Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CA3005633C (en) 2015-11-16 2023-11-21 Research Institute Of Nationwide Children's Hospital Materials and methods for treatment of titin-based myopathies and other titinopathies
WO2017100676A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
PL3436593T3 (pl) 2016-03-28 2023-03-27 Ultragenyx Pharmaceutical Inc. Sposoby inaktywacji termicznej adenowirusów
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
KR102695908B1 (ko) * 2016-07-21 2024-08-14 스파크 테라퓨틱스, 인코포레이티드 재조합 아데노-관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터
JP2019530737A (ja) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
MX2019002842A (es) 2016-09-12 2019-08-29 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas.
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
PT3534922T (pt) * 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
EP3576796A1 (en) 2017-02-01 2019-12-11 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
US11541131B2 (en) 2017-03-10 2023-01-03 Genethon Treatment of glycogen storage disease III
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
JP7221275B2 (ja) 2017-08-03 2023-02-13 ボイジャー セラピューティクス インコーポレイテッド Ａａｖを送達するための組成物および方法
US20200263199A1 (en) 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
MX2020004830A (es) 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.
EP3720500A4 (en) * 2017-12-05 2021-08-25 Applied Genetic Technologies Corporation FORMULATION OPTIMIZATION FOR VIRAL PARTICLES
MX2020007876A (es) 2018-01-31 2020-12-03 Res Inst Nationwide Childrens Hospital Terapia genica para la distrofia muscular de cinturas tipo 2c.
EP3749771A1 (en) 2018-02-07 2020-12-16 Genethon Hybrid regulatory elements
WO2019173434A1 (en) 2018-03-06 2019-09-12 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
CN112313331A (zh) 2018-04-27 2021-02-02 沃雅戈治疗公司 用于测量aadc病毒载体效力的方法
SG11202011296VA (en) 2018-05-15 2020-12-30 Voyager Therapeutics Inc Compositions and methods for the treatment of parkinson's disease
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
CN112601557B (zh) 2018-06-08 2025-06-06 诺华股份有限公司 用于测量药物产品效力的基于细胞的测定
MX2020014119A (es) 2018-06-29 2021-06-18 Res Inst Nationwide Childrens Hospital Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
KR20240014102A (ko) * 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
AU2019299964A1 (en) * 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
AU2019310459A1 (en) 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
EP3833745A1 (en) * 2018-08-10 2021-06-16 REGENXBIO Inc. Scalable method for recombinant aav production
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020072849A1 (en) 2018-10-04 2020-04-09 Voyager Therapeutics, Inc. Methods for measuring the titer and potency of viral vector particles
JP2022522995A (ja) 2019-01-18 2022-04-21 ボイジャー セラピューティクス インコーポレイテッド Ａａｖ粒子を生成するための方法及びシステム
MX2021010356A (es) 2019-02-26 2022-03-04 Res Inst Nationwide Childrens Hospital SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR.
US20220162640A1 (en) 2019-04-08 2022-05-26 Genethon Hybrid promoters for muscle expression
US20220143115A1 (en) 2019-04-19 2022-05-12 Regenxbio Inc. Adeno-Associated Virus Vector Formulations and Methods
BR112021020888A2 (pt) 2019-04-19 2021-12-21 Genethon Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23
EP3962536A1 (en) 2019-04-29 2022-03-09 Voyager Therapeutics, Inc. Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
US11155835B2 (en) 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
PT4017871T (pt) 2019-08-21 2024-04-22 Res Inst Nationwide Childrens Hospital Distribuição de vetor de vírus adeno-associado de alfasarcoglicano e o tratamento da distrofia muscular
TW202122582A (zh) 2019-08-26 2021-06-16 美商航海家醫療公司 病毒蛋白之控制表現
AU2020362119A1 (en) 2019-10-07 2022-05-26 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
WO2021078833A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric polypeptides and uses thereof
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
JP7807380B2 (ja) 2020-02-21 2026-01-27 アコーオス インコーポレイテッド ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
US20230212528A1 (en) * 2020-06-02 2023-07-06 Janssen Biotech, Inc. Materials and methods for viral purification
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
AU2021320395A1 (en) * 2020-08-07 2023-04-13 Janssen Biotech, Inc. Formulations for highly purified viral particles
US20230313152A1 (en) 2020-08-24 2023-10-05 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
JP2023552841A (ja) 2020-12-09 2023-12-19 ジェネトン ライソゾーム酸性リパーゼバリアント及びその使用
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022208342A1 (en) * 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
US20240240204A1 (en) * 2021-05-07 2024-07-18 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
WO2023042104A1 (en) 2021-09-16 2023-03-23 Novartis Ag Novel transcription factors
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
US20250235554A1 (en) 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
EP4514839A1 (en) 2022-03-17 2025-03-05 Innoskel Hybrid promoters and their use in osteolysis syndrome
EP4511392A1 (en) 2022-03-17 2025-02-26 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
US20250353883A1 (en) 2022-05-06 2025-11-20 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
JP2025524363A (ja) 2022-06-09 2025-07-30 ジェネトン 糖原病ｉｉｉの処置のためのｎ末端短縮型ｇｄｅ
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
EP2420247A1 (en) * 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
DE60335672D1 (de) * 2002-05-14 2011-02-17 Merck Sharp & Dohme Verfahren zur reinigung von adenovirus

Also Published As

Publication number Publication date
MX2019006353A (es) 2022-06-27
US7704721B2 (en) 2010-04-27
JP5769650B2 (ja) 2015-08-26
US20160083694A1 (en) 2016-03-24
ES2647477T3 (es) 2017-12-21
EP3290513B1 (en) 2022-09-07
US20110076744A1 (en) 2011-03-31
MXPA06014030A (es) 2007-10-08
JP2016195587A (ja) 2016-11-24
EP1751275B1 (en) 2017-08-16
JP2012143233A (ja) 2012-08-02
EP4170024A1 (en) 2023-04-26
EP3290513A1 (en) 2018-03-07
WO2005118792A1 (en) 2005-12-15
CA2569244C (en) 2017-02-14
DK3290513T3 (da) 2022-12-12
JP2014111625A (ja) 2014-06-19
JP2019058177A (ja) 2019-04-18
US9051542B2 (en) 2015-06-09
ES2932278T3 (es) 2023-01-17
BRPI0511764B8 (pt) 2021-05-25
US20170247664A1 (en) 2017-08-31
HUE060433T2 (hu) 2023-03-28
EP1751275A1 (en) 2007-02-14
BRPI0511764A (pt) 2008-01-08
CY1125798T1 (el) 2026-02-25
US20060035364A1 (en) 2006-02-16
BRPI0511764B1 (pt) 2017-10-24
CA2569244A1 (en) 2005-12-15
JP2008501339A (ja) 2008-01-24
EP1751275A4 (en) 2008-01-23
DK1751275T3 (da) 2017-11-27
HUE035418T2 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
MX360727B (es) Composiciones y metodos para evitar la agregacion del vector aav.
ES2683330T3 (es) Desinfectante de la piel basado en peróxido de hidrógeno
KR101057609B1 (ko) Ｎ,ｎ-디할로겐화 아미노산 및 유도체
ES2405307T3 (es) Composición de peróxido de hidrógeno de actividad biocida mejorada
ES2858299T3 (es) Eter aminas para mejorar el rendimiento esporicida
US12446578B2 (en) Antimicrobial compositions containing peroxyphthalic acid and/or salt thereof
KR20070098947A (ko) 하이포할로우스 산과의 조합의 ｎ-할로겐화 아미노산 및ｎ,ｎ-디할로겐화 아미노산
AU2009257390A1 (en) Method for treating chronic wounds with an extracellular polymeric substance solvating system
EP3979988A1 (en) Synthetic lipids for mrna delivery
CL2008003762A1 (es) Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes.
EP3383434B1 (en) Transduction buffer
MX350932B (es) Formulaciones virales liquidas.
BR112014001277A2 (pt) método melhorado para a produção de soluções de pesticida emulsionáveis
CR9831A (es) Formulaciones de plaguicidas con riesgo de cristalizacion y procedimiento para su obtencion
AR061830A1 (es) Formulacion liquida no acuosa altamente eficaz de piretroides
AR057319A1 (es) Composicion para la administracion topica y metodo para evitar o tratar infeccion o infestacion endoparasitica y ectoparasitica en un animal de sangre caliente
UY39674A (es) Nueva composición de concentrado en suspensión de ciclobutrifluram acuosa.
ES2639990T3 (es) Composición fungicida y método para controlar las enfermedades de las plantas
RU2522865C1 (ru) Состав для дезинфекции объектов животноводства и транспортных средств
ATE546147T1 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung
AR086672A1 (es) Formulaciones de furina recombinante
TWI681716B (zh) 液體乙醯基產生劑組合物
AR056558A1 (es) Metodos para estabilizar composiciones oftalmicas
US12532886B2 (en) Method of killing microbes using C3-C5 n-alkyl-gamma-butyrolactams and antimicrobial compositions containing same
BR112013032882B8 (pt) composição biocida, uso de uma composição, e, processo para controlar e lutar contra o crescimento de erva daninha em um campo de cultivo